MingMed Approved to Start US Trial of Immunotherapy

MingMed, a Guangzhou biopharma, has been approved to start US clinical trials of its small-molecule HPK1 inhibitor for cancer immunotherapy. The company says HPK1 promotes exhaustion of tumor immunity. By targeting HPK1, PRJ1-3024 is designed to regulate several varieties of immune cells and activate their synergistic anti-tumor effects. MingMed has developed novel therapies in the fields of ophthalmology, medical aesthetics, immuno-oncology and gene editing-based immunotherapy. It has 10 products in its R&D pipeline, most of them first-in-class medications for unmet medical needs. More details.... Share this with colleagues: // //